Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397 is registered in ClinicalTrials.gov with Syntrix Biosystems, Inc. as lead sponsor.

NCT NCT04245397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04245397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Lead sponsor
Syntrix Biosystems, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 30, 2020
Completion date
March 31, 2029
Enrollment
151 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes